

Edgar Filing: SIMTEK CORP - Form 10-Q/A

SIMTEK CORP
Form 10-Q/A
August 04, 2006

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q/A

(Mark One)

- ☒ Quarterly report pursuant to section 13 or 15(d) of the Securities
Exchange Act of 1934 for the Quarter ended March 31, 2006
OR
☐ Transition report pursuant to section 13 or 15 (d) of the Securities
Exchange Act of 1934

Commission file number 0-19027

SIMTEK CORPORATION
(Exact name of registrant as specified in its charter)

Colorado 84-1057605
(State or other jurisdiction (I.R.S. Employer Identification No.)
of incorporation or organization)

4250 Buckingham Drive, Suite 100,
Colorado Springs, Colorado 80907
(Address of principal executive offices) (Zip Code)

(719) 531-9444

Check whether the issuer (1) filed all reports required to be filed by Section
13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter
period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days. Yes ☒ No ☐
--- ---

Indicate by check mark whether the registrant is an accelerated filer (as
defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
--- ---

The total number of shares of Common Stock issued and outstanding as of
August 3, 2006 was 148,763,192.

Explanatory Note

We are filing this Amendment No. 1 on Form 10-Q/A to Simtek Corporation's
Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2006,
which was originally filed with the Securities and Exchange Commission (the
"SEC") on May 15, 2006 (the "Original Form 10-Q") to reflect that Simtek has
determined that it is appropriate to recognize the non-refundable advance
royalty payments under its License and Development Agreement, dated March 26,
2006, with Cypress Semiconductor Corporation ("Cypress") as royalty revenue upon

Edgar Filing: SIMTEK CORP - Form 10-Q/A

receipt from Cypress. Therefore, this Form 10-Q/A restates Simtek's consolidated financial statements as of and for the three months ended March 31, 2006 such that total revenue for such three month period is reported as \$5,778,000 (\$1,035,000 more than the \$4,743,000 reported in the Original Form 10-Q), net loss for such three months period is reported as \$901,000 (rather than the \$1,936,000 reported in the Original Form 10-Q), total liabilities are reduced from \$8,430,000 (as reported in the Original Form 10-Q) to \$7,395,000, accumulated deficit is reduced from \$48,127,000 (as reported in the Original Form 10-Q) to \$47,092,000, and total shareholders' equity is increased from \$2,008,000 (as reported in the Original Form 10-Q) to \$3,043,000. We decided to amend and restate after management and the audit committee of the Board of Directors discussed with our independent registered public accounting firm the recognition of such non-refundable advance royalty payments. We concluded that our financial statements for the three months ended March 31, 2006 should be restated.

Part I of this Form 10-Q/A contains more information about the restatement in "Note 2. Change in Accounting Principle," which accompanies the condensed consolidated financial statements in Item 1.

This Form 10-Q/A speaks as of March 31, 2006, and except as noted herein, we have not materially modified or updated the disclosures herein for events that occurred at a later date. Events occurring after the date of the Original Form 10-Q, and other disclosures necessary to reflect subsequent events, have been addressed, in accordance with applicable disclosure requirements, in our Form 8-Ks filed after March 31, 2006 will be addressed, in accordance with applicable disclosure requirements, in our Form 10-Q for the three months ended June 30, 2006.

SIMTEK CORPORATION

INDEX

For the Quarter Ended March 31, 2006

PART 1. FINANCIAL INFORMATION

ITEM 1	Page

Condensed Consolidated Balance Sheets as of March 31, 2006 and December 31, 2005	4
Condensed Consolidated Statements of Operations for the three months ended March 31, 2006 and 2005	5
Condensed Consolidated Statements of Cash Flows for the	

Edgar Filing: SIMTEK CORP - Form 10-Q/A

three months ended March 31, 2006 and 2005	6
Notes to Condensed Consolidated Financial Statements	7-14
ITEM 2	
Managements Discussion and Analysis of Financial Condition and Results of Operations	15
ITEM 3	
Quantitative and Qualitative Disclosures about Market Risk	21
ITEM 4	
Controls and Procedures	22
PART 2. OTHER INFORMATION	
ITEM 1	
Legal Proceedings	23
ITEM 2	
Unregistered Sales of Equity Securities and Use of Proceeds	23
ITEM 3	
Defaults Upon Senior Securities	23
ITEM 4	
Submission of Matters to a Vote of Security Holders	23
ITEM 5	
Other Information	23
ITEM 6	
Exhibits and Reports on Form 8-K	23
SIGNATURES	24

SIMTEK CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (Amounts in thousands, except par value and share amounts)

ASSETS -----

March 31, 2006

(As Restated)
(Unaudited)

CURRENT ASSETS:

Cash and cash equivalents	\$ 2,814
---------------------------	----------

Edgar Filing: SIMTEK CORP - Form 10-Q/A

Restricted investments	2,281
Accounts receivable - trade, net	2,854
Inventory, net	2,572
Prepaid expenses and other current assets	115
Deposits	--

Total current assets	10,636
EQUIPMENT AND FURNITURE, net	621
DEFERRED FINANCING COSTS AND DEBT ISSUANCE COSTS	103
GOODWILL	914
NON-COMPETITION AGREEMENT	8,459
OTHER ASSETS	37

TOTAL ASSETS	\$ 20,770
	=====
	LIABILITES AND SHAREHOLDERS' EQUITY

CURRENT LIABILITIES:	
Accounts payable	\$ 3,049
Accrued expenses	1,022
Accrued vacation payable	172
Accrued wages	152
Obligation under capital leases	--
Debentures, current	360

Total current liabilities	4,755
DEBENTURES, NET OF CURRENT	2,640

Total liabilities	7,395
Temporary equity, consisted of 68,750,000 shares of common stock, \$0.01 par value, subject to cash penalties under registration rights agreements, net of financing costs of \$667,542	10,332
COMMITMENTS AND CONTINGENCIES	
SHAREHOLDERS' EQUITY:	
Preferred stock, \$1.00 par value; 2,000,000 shares authorized, none issued	--
Common stock, \$.01 par value; 300,000,000 shares authorized, 78,170,823 and 78,160,823 shares issued and outstanding at March 31, 2006 and December 31, 2005, excluding temporary equity	782
Additional paid-in capital	49,366
Treasury stock, at cost; 10,000 shares	(13)
Accumulated deficit	(47,092)
Accumulated other comprehensive income: Cumulative translation adjustment	--

Total shareholders' equity	3,043

TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	\$ 20,770
	=====

The accompanying notes are an integral part of these condensed consolidated financial stat

Edgar Filing: SIMTEK CORP - Form 10-Q/A

SIMTEK CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
(Amounts in thousands, except share and per share amounts)

	For the three months end

	2006

	(As Restated)
REVENUE	
Product sales, net	\$ 4,743
Royalty revenue	1,035

Total Revenue	5,778
Cost of sales	3,470

GROSS PROFIT	2,308
OPERATING EXPENSES:	
Research and development costs	1,545
Sales and marketing	944
General and administrative	699

Total operating expenses	3,188

LOSS FROM OPERATIONS	(880)
OTHER INCOME (EXPENSE):	
Interest income	40
Interest expense	(60)
Other expense	(1)

Total other expense	(21)

LOSS FROM CONTINUING OPERATIONS	
BEFORE PROVISION FOR INCOME TAXES	(901)
Provision for income taxes	--

LOSS FROM CONTINUING OPERATIONS	(901)
LOSS FROM DISCONTINUED OPERATIONS	--

NET LOSS	\$ (901)
	=====
NET LOSS PER COMMON SHARE:	
Basic and diluted	
Loss from continuing operations	\$ (.01)

Edgar Filing: SIMTEK CORP - Form 10-Q/A

Loss from discontinued operations	\$ --

Total	\$ (.01)
	=====
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:	
Basic and diluted	146,920,823
	=====

The accompanying notes are an integral part of these condensed consolidated financial sta

5

SIMTEK CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) (Amounts in thousands)

	Three Months Ende

	2006

	(As Restated)
CASH FLOWS FROM OPERATING ACTIVITIES:	
Net loss	\$ (901)
Loss from discontinued operations	--
Adjustments to reconcile net loss to net cash used in operating	
Activities:	
Depreciation and amortization	107
Expense related to stock options	119
Amortization of non-competition agreement	451
Net change in allowance accounts	353
Deferred financing fees	8
Changes in assets and liabilities:	
(Increase) decrease in:	
Accounts receivable	(1,387)
Inventory	(943)
Prepaid expenses and other	567
Increase (decrease) in:	
Accounts payable	224
Accrued expenses	(178)

Net cash used in operating activities of continuing operations	(1,580)
Net cash provided by operating activities of discontinued	
operations	--

Net cash used in operating activities	(1,580)

CASH FLOWS FROM INVESTING ACTIVITIES:	
Purchase of equipment and furniture, net	(157)
Purchase of certain assets from ZMD	(38)

Edgar Filing: SIMTEK CORP - Form 10-Q/A

Net cash used in investing activities of continuing operations	(195)
Net cash used in investing activities of discontinued operations	--
Net cash used in investing activities	(195)
CASH FLOWS FROM FINANCING ACTIVITIES:	
Payments on capital lease obligation	(13)
Funds receiving from December 2005 equity financing, net	1,874
Warrants issued for license rights	965
Exercise of stock options	--
Net cash provided by financing activities	2,826
Effect of exchange rate changes on cash	(3)
NET CHANGE IN CASH AND CASH EQUIVALENTS	1,048
CASH AND CASH EQUIVALENTS, beginning of period	1,766
CASH AND CASH EQUIVALENTS, end of period	\$ 2,814
Cash paid for interest	\$ 56

The accompanying notes are an integral part of these condensed consolidated financial statements.

6

SIMTEK CORPORATION NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

1. Basis of Presentation

The consolidated financial statements include the accounts of Simtek and its wholly owned subsidiaries. Intercompany accounts and transactions have been eliminated. The financial statements included herein are presented in accordance with the requirements of Form 10-Q and consequently do not include all of the disclosures normally made in the registrant's annual Form 10-K filing. These financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in the Annual Report and Form 10-K and Annual Report and Form 10-K/A for Simtek Corporation ("Simtek" or the "Company") filed on April 7, 2006 and April 28, 2006, respectively for fiscal year 2005.

In the opinion of management, the unaudited financial statements reflect all adjustments of a normal recurring nature necessary to present a fair statement of the results of operations for the respective interim periods. The year-end balance sheet data was derived from audited financial statements, but does not include all disclosures required by accounting principles generally accepted in the United States of America. Results of operations for the interim periods are not necessarily indicative of the results of operations for the full fiscal year.

Stock-Based Compensation

Edgar Filing: SIMTEK CORP - Form 10-Q/A

----- Adoption of SFAS 123(R)

Effective January 1, 2006, the Company adopted the fair value recognition provisions of Statement of Financial Accounting Standard 123(R) "Share-Based Payment" ("SFAS 123(R)") using the modified prospective transition method. In addition, the Securities and Exchange Commission issued Staff Accounting Bulletin No. 107 "Share-Based Payment" ("SAB 107") in March, 2005, which provides supplemental SFAS 123(R) application guidance based on the views of the SEC. Under the modified prospective transition method, compensation cost recognized in the quarterly period ended March 31, 2006 includes: (a) compensation cost for all share-based payments granted prior to, but not yet vested as of January 1, 2006, based on the grant date fair value estimated in accordance with the original provisions of SFAS No. 123, and (b) compensation cost for all share-based payments granted beginning January 1, 2006, based on the grant date fair value estimated in accordance with the provisions of SFAS 123(R). In accordance with the modified prospective transition method, results for prior periods have not been restated.

The adoption of SFAS 123(R) resulted in stock compensation expense for the quarterly period ended March 31, 2006 of \$119,000 to loss from continuing operations and loss before income taxes. The Company did not recognize a tax benefit from the stock compensation expense because the Company considers it is more likely than not that the related deferred tax assets, which have been reduced by a full valuation allowance, will not be realized. The following table summarizes the effects of the share-based compensation resulting from the application of SFAS No. 123(R) to options granted under the Company's stock option plan.

Three Months
Ended
March 31, 2006

(In thousands except per share amounts)

Research and development	\$ 39
Sales and marketing	16
General and administrative	64

Share-based compensation effect on loss from continuing operations before provision for income taxes	\$ 119
Provision for income taxes	-

Net share-based compensation effects on net loss	\$ 119
	=====
Share-based compensation effects on basic and diluted loss per common share	\$ -
	=====
Share-based compensation effects on cash flow from operations	\$ 119
	=====

Edgar Filing: SIMTEK CORP - Form 10-Q/A

The Black-Scholes option-pricing model was used to estimate the option fair values. The option-pricing model requires a number of assumptions, of which the most significant are, expected stock price volatility and the expected option term (the amount of time from the grant date until the options are exercised or expire). Expected volatility was calculated based upon actual historical stock price movements over the most recent periods ending March 31, 2006 equal to the expected option term. In accordance with SFAS No. 123(R), the Company adjusts share-based compensation on a quarterly basis for changes to the estimate of expected forfeitures based on actual forfeiture experience. The effect of adjusting the forfeiture rate for all expense amortization after January 1, 2006 is recognized in the period the forfeiture estimate is changed. The effect of forfeiture adjustments in the first quarter of 2006 was insignificant. The expected option term was calculated using the "simplified" method permitted by SAB 107.

SFAS 123(R) requires tax benefits resulting from tax deductions in excess of the compensation cost recognized for those options ("excess tax benefits") to be classified and reported as both an operating cash outflow and a financing cash inflow upon adoption of SFAS 123(R). As discussed in Note 7 - Taxes from the Company's report on Form 10-K for the period ending December 31, 2005, as a result of the Company's net operating losses, the excess tax benefits that would otherwise be available to reduce income taxes payable have the effect of increasing the Company's net operating loss carry forwards. Accordingly, because the Company is not able to realize these excess tax benefits, such benefits have not been recognized in the condensed statement of cash flow for the quarterly period ended March 31, 2006.

Pro-Forma Stock Compensation Expense for the Quarterly Period Ended March 31, 2005

Prior to January 1, 2006, as permitted under the SFAS No. 123, Accounting for Stock-Based Compensation, the Company accounted for its stock-based compensation in accordance with the provisions of Accounting Principles Board (APB) Opinion No. 25, Accounting for Stock Issued to Employees. As such, compensation expense was recorded on the date of grant if the current market price of the underlying stock exceeds the exercise price. Certain pro forma net loss and EPS disclosures for employee stock option grants are included below as if the fair value method as defined in SFAS No. 123 had been applied. Transactions in equity instruments with non-employees for goods or services are accounted for by the fair value method. Had compensation cost been determined based on the fair value at the grant dates for awards under employee stock based compensation plans consistent with the fair value method for the quarter ending March 31, 2005, the Company's net loss and EPS would have been increased to the pro forma amounts indicated below.

	Three Months ----- Ended March 31, ----- 2005 ----
(In thousands except per share amounts)	
Net loss as reported	\$ (1,013)
Add: Stock based compensation included in reported	
Net loss	-
Deduct: Fair value of stock based compensation	(141)

Proforma net loss	\$ (1,154) =====
Net loss as reported - basic and diluted	\$ (.02)

Edgar Filing: SIMTEK CORP - Form 10-Q/A

Proforma net loss - basic and diluted

\$ (.02)

8

SIMTEK CORPORATION NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

In accordance with the modified prospective transition method of SFAS 123(R), the prior comparative quarterly results have not been restated.

Stock Options as of the Quarterly Period Ended March 31, 2006

The Company adopted a Non-Qualified Stock Option Plan in 1994, as amended, that authorizes 18,600,000 non-qualified stock options that may be granted to directors, employees, and consultants. The plan permits the issuance of non-statutory options and provides for a minimum exercise price equal to 100% of the fair market value of the Company's common stock on the date of grant. The maximum term of options granted under the plans are 10 years and options granted to employees expire three months after the termination of employment. In 2004, the Non-Qualified Stock Option Plan was extended for 10 more years. None of the options may be exercised during the first six months of the option term.

The following table summarizes stock options outstanding and changes during the quarterly period ended March 31, 2006:

		Outstanding Op
	Number of Shares	Weighted Average Exercise Price
Options outstanding at January 1, 2006.....	7,969,363	\$0.62
Granted.....	640,000	0.27
Exercised.....	-	-
Cancelled or forfeited.....	(120,000)	(1.25)
Options outstanding at March 31, 2006.....	8,489,363	\$0.56
Options exercisable at March 31, 2006.....	5,193,252	\$0.65

There were no options exercised in the period ended March 31, 2006. Shares available for grant under the Plan as of March 31, 2006 were 5,665,017.

Edgar Filing: SIMTEK CORP - Form 10-Q/A

9

SIMTEK CORPORATION NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Stock options outstanding and currently exercisable at March 31, 2006 are as follows:

Outstanding				Exerc
Weighted Average				
Exercise Price	Number Outstanding	Remaining Contractual Life in Months	Weighted Average Exercise Price	Number Exercisable
\$0.14-\$0.35	1,780,188	34	\$ 0.23	1,140,188
\$0.365-\$0.60	3,267,716	53	\$ 0.46	1,403,251
\$0.62-\$0.90	2,364,125	59	\$ 0.66	1,572,479
\$1.125-\$1.53	927,334	37	\$ 1.26	927,334
\$1.90	150,000	59	\$ 1.90	150,000
	-----			-----
	8,489,363			5,193,252
	=====			=====

Total estimated unrecognized compensation cost from unvested stock options as of March 31, 2006 was approximately \$1 million, which is expected to be recognized over the next three years.

The weighted average per share fair value of stock options granted during the quarterly periods ending March 31, 2006 and 2005 was \$0.1727 and \$0.3856, respectively. The fair value was estimated as of the grant date using the Black-Scholes option pricing model with the following assumptions:

	Three Months Ended March 31,	
	2006	2005
Volatility	85%	83%
Expected option term	4 years	4 years
Risk-free interest rate	4.59%	3.54%
Expected dividend yield	0%	0%

Modifications of Stock Options Granted

In May 2005, the Company accelerated vesting of certain unvested and

Edgar Filing: SIMTEK CORP - Form 10-Q/A

out-of-the-money stock options previously awarded to employees and officers. Because the price of the Company's common stock was \$0.57 on the day of acceleration, the options, which are exercisable at \$0.62 and above, had no economic value on the date of acceleration. As a result of the acceleration, options to purchase approximately 1.7 million shares of Simtek common stock are now exercisable. Options held by non-employee directors were excluded from the vesting acceleration.

10

SIMTEK CORPORATION NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Non-competition Agreement

In December 2005, the Company entered into a non-competition agreement with Zentrum Mikroelektronik Dresden AG ("ZMD") as part of the acquisition of ZMD's nvSRAM product line. The Company assigned a value of \$8,910,000 to the non-competition agreement in December 2005. The value assigned to the non-competition agreement is being amortized on a straight-line basis over its five-year life. The Company recorded an expense, for the amortization, of approximately \$451,000 to sales and marketing for the three months ended March 31, 2006.

Goodwill

Goodwill represents the excess of the total amount paid to ZMD for the nvSRAM assets acquired on December 30, 2005 and the fair value assigned to specific assets. This amount will not be amortized, but will be reviewed for impairment on a periodic basis. As of March 31, 2006 no impairment of value has been recorded.

Accumulated other comprehensive income (loss)

The functional currency for Simtek GmbH is the local currency, the Euro. Assets and Liabilities for this foreign operation are translated at the exchange rate in effect at the balance sheet date, and income and expenses are translated at average exchange rates prevailing during the period. Translation gains or losses are included within shareholders' equity as part of accumulated other comprehensive income (loss).

2. Change in Accounting Principle

The Company originally recorded the receipt of the non-refundable prepaid royalties received from Cypress on March 24, 2006 as a liability to be recognized as revenue in the future based upon shipments of products by Cypress to its customers (See Note 7 below). However, the Company subsequently determined that the non-refundable prepaid royalties are more appropriately accounted for as minimum royalty payments as described in Staff Accounting Bulletin 101 "Revenue Recognition in Financial Statements." All of the revenue recognition criteria contained in Statement of Financial Accounting Concepts No. 5 "Recognition and Measurement in Financial Statements of Business Enterprises"

Edgar Filing: SIMTEK CORP - Form 10-Q/A

have been met. Under the previous method of accounting, if Cypress does not actually sell product, Simtek would never recognize the revenue. Since Simtek fulfilled all of its obligations prior to receipt of the payment, the non-refundable payments are more properly accounted for as minimum royalty payments and recorded as revenue when received.

The following table reflects the amounts as previously reported and as restated:

	As Reported	Restated
(Amounts in thousands)		
Consolidated Balance Sheet:		
Prepaid royalties	\$ 1,035	\$ --
Total liabilities	\$ 8,430	\$ 7,395
Accumulated deficit	\$ (48,127)	\$ (47,092)
Total shareholders' equity	\$ 2,008	\$ 3,043
Consolidated Statement of Operations:		
Royalty revenue	\$ --	\$ 1,035
Total revenue	\$ 4,743	\$ 5,778
Gross profit	\$ 1,273	\$ 2,308
Loss from operations	\$ (1,915)	\$ (880)
Net loss	\$ (1,936)	\$ (901)

11

SIMTEK CORPORATION NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

3. Liquidity

During the three months ended March 31, 2006 and the twelve months ended December 31, 2005, the Company incurred a net loss of approximately \$1,936,000 and \$5,785,000, respectively and has an accumulated deficit of \$48,127,000 as of March 31, 2006. The Company was also not in compliance with its debentures throughout 2005 and the first three months of 2006, but was successful in obtaining waivers through April 1, 2007 from the debenture holders. The Company will issue the debenture holders a total of 50,000 warrants for receipt of the waiver. The Company has working capital of approximately \$4,846,000 as of March 31, 2006.

The Company operates in a volatile industry, whereby its average selling prices and product costs are influenced by competitive factors. Furthermore, the Company continues to incur significant research and development costs for product development. These factors create pressures on sales, costs, earnings and cash flows, which will impact liquidity.

If the Company is unable to achieve profitable operations in 2006 it may result in increased liquidity pressure on the Company, whereby it might be required to enter into debt or equity arrangements that may not be as otherwise favorable to the Company.

Edgar Filing: SIMTEK CORP - Form 10-Q/A

4. Revenue Recognition

Revenue Recognition - Product sales revenue is recognized when a valid purchase order has been received with a fixed price and the products are shipped to customers FOB origin (Colorado Springs, Colorado or Dresden, Germany), including distributors. Based on historic business with the majority of the Company's customers and, in the case of new customers, the Company is reasonably assured that collectibility on our shipments will occur. Customers receive a one-year product warranty and sales to distributors are subject to a limited product exchange program and a price protection in the event of changes in the Company's product price. The Company provides a reserve for possible product returns, product price protection and warranty costs at the time the sale is recognized. The Company has a detailed procedure to ensure that its estimates for reserves are reasonable and reliable. The reserve for product returns is based on the actual inventory value of the Company's semiconductor products held by its distributors. The Company's distributors are permitted to rotate up to 5% of their stock every six months with the stipulation that they must submit a replacement order of equal dollar value to the stock that they are returning. The reserve for price protection is used when the Company authorizes special pricing to one of its distributors for a specific customer. To date, the estimates have not been materially different from the credits we have issued under these reserves.

Revenue from royalties related to non-refundable prepaid royalty payments is recognized upon receipt. Revenue from royalties related to sales of products by license partners is recognized upon the notification to us of shipment of product from the Company's technology license partners to direct customers.

5. Inventories

The Company records inventory using the lower of cost (first-in, first-out) or market. Inventory at March 31, 2006 and December 31, 2005 included:

	March 31, 2006	December 31, 2005
(In Thousands)		
Raw Materials	\$ 67	\$ 33
Work in progress	1,476	1,096
Finished Goods	1,588	1,056
	-----	-----
	3,131	2,185
Less reserves for excess inventory	(559)	(117)
	-----	-----
	\$ 2,572	\$ 2,068
	=====	=====

SIMTEK CORPORATION NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

6. Convertible Debentures

On July 1, 2002, the Company received funding of \$3,000,000 in a financing transaction with Renaissance Capital Growth and Income Fund III, Inc., Renaissance US Growth & Investment Trust PLC and BFSUS Special Opportunities Trust PLC. RENN Capital Group, Inc. is the agent for the RENN investment funds. One of the Company's directors holds the position of Senior Vice President of

Edgar Filing: SIMTEK CORP - Form 10-Q/A

RENN Capital Group. The \$3,000,000 funding consists of convertible debentures with a 7-year term at a 7.5% per annum interest rate. Each fund equally invested \$1,000,000. The holder of the debenture shall have the right, at any time, to convert all, or in multiples of \$100,000, any part of the Debenture into fully paid and nonassessable shares of Simtek Corporation common stock. The debentures were originally convertible into Simtek common stock at \$0.312 per share, which was in excess of the market price per share on July 1, 2002. Through March 31, 2006, the Company was not in compliance with two of the covenants set forth in the loan agreement. These covenants relate to the interest coverage ratio and debt to equity ratio. On May 10, 2006, the Company received a waiver for the two covenants through April 1, 2007. The Company will issue the debenture holders a total of 50,000 warrants for receipt of the waiver. However, significant variances in future actual operations from the Company's current estimates could result in the reclassification of this note to current liabilities. The Convertible Debentures allows for an adjustment in the conversion price, if the Company issues Common Stock in connection with an equity financing, where the sale price is less than the conversion price of \$0.312. This occurred in December 2005 in connection with the common stock sale of \$11,000,000 at a price of \$0.16 per share. Pursuant to the terms of the 2002 convertible debentures, the Company agreed with the RENN Capital Group that the conversion price would be reduced to \$0.22 per share. Based on the conversion rate of \$0.22 per share, each RENN investment fund is entitled to 4,545,455 shares upon conversion.

On June 28, 2005, the Company received a waiver from the debenture holders extending until July 1, 2006 the commencement date for principal payments of the \$3 million aggregate principal amount 7.5% convertible debentures issued by the Company in 2002. The original terms of the debentures required the Company to make monthly principal payments of \$10 per \$1,000 of the then remaining principal amount, beginning on June 28, 2005. The Company will still be required to make interest payments. Under the terms of the waiver, monthly principal payments of \$13.33 per \$1,000 of the then remaining outstanding principal amount will commence on July 1, 2006. The final maturity date remains as June 28, 2009. As consideration for the extension, the Company has issued to the debenture holders warrants to purchase 200,000 shares of Simtek common stock at \$0.50 per share, a premium to the market price on the date of the waiver. The Company estimated the value of the warrants at the time of grant, using the Black Scholes option-pricing model, to be approximately \$62,000. The Company recognized \$4,000 as additional interest expense for the three months ending March 31, 2006.

7. Non-Refundable Prepaid Royalties

On March 24, 2006, the Company entered into a Development and License Agreement with Cypress pursuant to which, among other things, Cypress agreed to license certain intellectual property from the Company to develop and manufacture standard, custom and embedded nvSRAM products and Cypress has agreed to pay to the Company \$4,000,000 in non-refundable pre-paid royalties of which \$2 million was paid upon signing of the agreement and \$1 million is payable on each of June 30, 2006 and December 31, 2006. In addition, the Company licensed rights to use certain intellectual property from Cypress for use in its products. As part of the Development and License Agreement, the Company agreed to issue to Cypress warrants to purchase 20 million shares of the Company's common stock for \$0.75 per share. The warrants have a ten year life. The warrants will be issued upon receipt of each of the prepaid royalty amounts. As of March 31, 2006, the Company received \$2,000,000 from Cypress in pre-paid royalties. In addition, the Company has issued warrants to purchase 10 million shares of common stock. The value of the warrants issued of \$965,000 was determined by an independent valuation firm and has been recorded as an increase in additional paid in capital. The net balance of the non-refundable prepaid royalties of \$1,035,000 was recognized as revenue at the time the payment was received.

SIMTEK CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

8. Geographic Concentration

Sales of the Company's semiconductor products by location for the three months ended March 31, 2006 and 2005 were as follows:

	Three Months Ended March 31,	
	2006	2005
	-----	-----
United States	19%	28%
Europe	28%	17%
Far East	44%	44%
All Others	9%	11%
	-----	-----
	100%	100%
	====	====

9. Accumulated Other Comprehensive Income (Loss)

Accumulated other comprehensive income (loss) net of tax is as follows:

	Foreign Currency Translation Adjustment
Balance at January 1, 2006	\$ -
Current period change	-

Balance March 31, 2006	\$ -

10. Discontinued Operation

On August 30, 2005, the Company, along with the Company's wholly-owned subsidiary, Q-DOT, Inc. ("Q-DOT"), entered into an Asset Purchase Agreement with Hittite Microwave Corporation ("Hittite") and a wholly-owned subsidiary of Hittite, HMC Acquisition Corporation ("HMC Acquisition"), whereby substantially all of the assets of Q-DOT were sold to HMC Acquisition in exchange for a cash payment of approximately \$2.2 million. The Company realized a net gain of approximately \$1,687,000. In addition, Hittite assumed certain future obligations of Q-DOT, including obligations related to Q-DOT's real estate lease and certain software license agreements. Incident to the Asset Purchase Agreement, the parties also entered an Escrow Agreement, whereby \$200,000 of the purchase price was placed in escrow for one year to secure certain indemnification obligations of Simtek and Q-DOT. In addition, the parties entered into a Confidentiality, Non-Disclosure and Restrictive Covenant Agreement, whereby, among other things, Simtek and Q-DOT agreed not to compete against Hittite and HMC Acquisition for a period of four years with respect to certain businesses relating to Q-DOT's operations.

Edgar Filing: SIMTEK CORP - Form 10-Q/A

In accordance with SFAS No. 144, the consolidated financial statements of the Company have been recast to present this business as a discontinued operation. Accordingly, the revenues, the costs and expenses and assets and liabilities of the discontinued operation have been excluded from the respective captions in the accompanying Consolidated Statements of Operations and Consolidated Balance Sheets. In addition, certain of the Notes to the Consolidated Financial Statements have been recast for all periods to reflect the discontinuance of this operation.

14

SIMTEK CORPORATION

ITEM 2 MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis in this quarterly report on Form 10-Q is intended to provide greater details of the results of operations and financial condition of our Company. The following discussion should be read in conjunction with our condensed consolidated financial statements and notes thereto and other financial data included elsewhere herein. Certain statements under this caption constitute forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The reader should not place undue reliance on these forward looking statements for many reasons including those risks discussed in this document. In addition, when used in this quarterly report, the words "believes," "anticipates," "expects," "plans," "intends" and similar expressions are intended to identify forward-looking statements. Forward-looking statements and statements of expectations, plans and intent are subject to a number of risks and uncertainties. Actual results in the future could differ materially from those described in the forward-looking statements, as a result, among other things, of changes in technology, customer requirements and needs. We undertake no obligation to release publicly the results of any revisions to these forward-looking statements that may be made to reflect any future events or circumstances.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

Our consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, which require us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and the related disclosures. Our accounting policies are discussed in Note 1 of the Notes to Consolidated Financial Statements included in our 2005 Form 10-K. The estimates used by us are based upon our historical experiences combined with our understanding of current facts and circumstances. Certain of our accounting policies are considered critical as they are both important to the portrayal of our financial condition and the results of our operations and require significant or complex judgments on our part. We believe that the following represent the critical accounting policies of Simtek as described in Financial Reporting Release No. 60, Cautionary Advice Regarding Disclosure About Critical Accounting Policies, which was issued by the Securities and Exchange Commission: inventories; deferred income taxes; allowance for doubtful accounts; and, allowance for sales returns.

The valuation of inventories involves complex judgments on our part. Excess

Edgar Filing: SIMTEK CORP - Form 10-Q/A

finished goods inventories are a natural component of market demand of semiconductor devices. We continually evaluate and balance the levels of inventories based on sales projections, current orders scheduled for future delivery and historical product demand. While certain finished goods items will sell out, quantities of other finished goods items will remain. These finished goods are reserved as excess inventory. We believe we have adequate controls with respect to the amount of finished goods inventories that are anticipated to become excess. While we believe this process produces a fair valuation of inventories, changes in general economic conditions of the semiconductor industry could materially affect valuation of our inventories.

The allowance for doubtful accounts reflects a reserve that reduces customer accounts receivable to the net amount estimated to be collectible. Estimating the credit worthiness of customers and the recoverability of customer accounts requires management to exercise considerable judgment. In estimating uncollectible amounts, we consider factors such as industry specific economic conditions, historical customer performance and anticipated customer performance. While we believe our processes to be adequate to effectively quantify our exposure to doubtful accounts, changes in industry or specific customer conditions may require us to adjust our allowance for doubtful accounts.

15

SIMTEK CORPORATION

We record an allowance for sales returns as a net adjustment to customer accounts receivable. The allowance for sales returns consists of two separate segments, distributor stock rotation and distributor price reductions. When we record the allowance, the net method reduces customer accounts receivables and gross sales. Generally, we calculate the stock rotation portion of the allowance based upon actual reported distributor inventory levels. The contracts we have with certain of our distributors generally allow them to return to us a 5% percent of their inventory every 6 months, in exchange for inventory that better meets their demands. At times, our distributors reduce the selling price of a specific device in order to meet competition related to a specific end customer program, which we support through a credit back to the distributor for that specific program. When this occurs, we record an allowance for potential credit that our distributors will be requesting. This allowance is based on approved pricing changes, inventory affected and historical data. We believe that our processes to adequately predict our allowance for sales returns are effective in quantifying our exposures due to industry or specific customer conditions.

We record an allowance that directly relates to the warranty of our products for one year. The allowance for warranty return reduces our gross sales. This allowance is calculated by looking at annual revenues and historical rates of our products returned due to warranty issues. While we believe this process adequately predicts our allowance for warranty returns, changes in the manufacturing or design of our product could materially affect valuation of our warranties.

We assess the impairment of long-lived assets when events or changes in circumstances indicate that the carrying value of the assets may not be recoverable. Factors that we consider in deciding when to perform an impairment

Edgar Filing: SIMTEK CORP - Form 10-Q/A

review include significant under-performance of the business in relation to expectations, significant negative industry or economic trends, and significant changes or planned changes in our use of the assets. Recoverability of assets that will continue to be used in our operations is measured by comparing the carrying amount of the assets to our estimate of the related future net cash flows. If the asset's carrying amount is not recoverable through the related cash flows, the asset is considered to be impaired. The impairment is measured by the difference between the asset's carrying amount and its fair value, based on the best information available, including market prices or discounted cash flows.

Goodwill represents the excess of the purchase price over the fair value of identifiable net tangible and intangible assets acquired in the acquisition of the nvSRAM assets from ZMD. Goodwill is required to be tested for impairment. We performed goodwill impairment testing as of March 31, 2006, and determined that no impairment existed at that date. This assessment requires estimates of future revenue, operating results and cash flows, as well as estimates of critical valuation inputs such as discount rates, terminal values and similar data. We will continue to perform periodic and annual impairment analyses of goodwill. As a result of such impairment analyses, impairment charges may be recorded and may have a material adverse impact on our financial position and operating results. Additionally, we may make strategic business decisions in future periods which impact the fair value of goodwill, which could result in significant impairment charges. There can be no assurance that future goodwill impairments will not occur.

We have recorded a valuation allowance on deferred tax assets. Future operations may change our estimate in connection with potential utilization of these assets.

Overview

Total revenue for the three months ended March 31, 2006 was \$5.8 million, including \$1.0 million of royalty revenue. Total unit shipments of our semiconductor memory products increased for the three months ended March 31, 2006 as compared to the three months ended March 31, 2005. Our net product

SIMTEK CORPORATION

revenue was \$4,743,000 for the three months ended March 31, 2006 up from the \$2,976,000 for the comparable period of 2005, an approximate 59% increase. This increase was due primarily to increased product demand and the addition of revenue from customers previously serviced by ZMD prior to the acquisition of the nvSRAM product line from ZMD in December 2005.

An approximate decrease of 3% in product gross margin percentage and increased operating expenses had an impact on our profitability for the three months ended March 31, 2006 compared to the three months ended March 31, 2005. The increase in operating expenses includes non-cash charges of \$448,000 for amortization of the non-compete agreement with ZMD and \$119,000 for expenses related to employee stock options, plus first-time operating expenses of \$225,000 for our European subsidiary, Simtek GmbH.

Edgar Filing: SIMTEK CORP - Form 10-Q/A

Consolidated revenue, from our product sales, for the first quarter of 2006 of \$4,745,000 compared to \$2,794,000 in the fourth quarter of 2005, an increase of 70 percent, reflecting the effects of adding the nvSRAM business that was acquired from ZMD, as well as increasing customer demand. During the first quarter of 2006, we recorded royalty revenue of \$1,035,000 received from Cypress. Net loss for the first quarter of 2006 was \$901,000, or \$0.01 per share, compared to a net loss of \$1,851,000, or \$0.02 per share, in the fourth quarter of 2005. Net loss in the first quarter includes non-cash charges of \$448,000 for amortization of the non-compete agreement with ZMD, and \$119,000 for expenses related to employee stock options, plus "first-time" operating expenses of approximately \$225,000 for Simtek GmbH. There were no comparable charges in the fourth quarter of 2005 for these three first-quarter 2006 charges.

Results of Operations:

Revenues

The following table sets forth our net revenues for semiconductor devices by product markets for the three months ended March 31, 2006 and 2005 (in thousands):

	Three Months Ended March 31,		
	2006	2005	Variance
	----	----	-----
Commercial	\$ 3,951	\$ 2,407	\$ 1,544
High-end industrial and military	792	569	\$ 223
	-----	-----	-----
Total Semiconductor Revenue	\$ 4,743	\$ 2,976	\$ 1,767
	=====	=====	=====

Commercial revenues include revenue generated from our 0.8-micron products built from silicon wafers received from Chartered Semiconductor or purchased as finished units from ZMD, and from our 0.25-micron products built from silicon wafers received from Dongbu Electronics (DBE). Commercial revenues increased by \$1,544,000 for the three months ended March 31, 2006 as compared to the three months ended March 31, 2005. As stated previously, this increase was due primarily to increased product demand and the addition of revenue from customers previously serviced by ZMD prior to the acquisition of the nvSRAM product line from ZMD in December 2005. Other factors affecting the increase were an increase in unit shipments partially offset by a slight decrease in average selling prices, which was primarily due to increased price competition at our largest, high-volume customers and their subcontractors. Unit shipments increased due to increased product demand and the addition of the product line purchased at the end of 2005.

High-end industrial and military product revenues accounted for an increase of approximately \$223,000 for the three months ended March 31, 2006 as compared to the same period in 2005. The increase was due to the addition of new customer demand for our products and increased pricing to certain of our customers for industrial and military products.

SIMTEK CORPORATION

One distributor and one direct customer together accounted for approximately 23% of our revenue for the quarter ended March 31, 2006. Products sold to distributors are sold without material recourse. Distributors sell our products to various end customers. If one of these distributors was to terminate its relationship with us, we believe that there would not be a material impact on our product sales, as we believe that we would be able to service these various end customers through other distributors.

Cost of Sales and Gross Profit

We recorded cost of sales of \$3,470,000 and \$2,071,000 for the three months ended March 31, 2006 and 2005, respectively. These costs reflect an approximate 3% decrease in gross margin percentages for our semiconductor products, for the three months ended March 31, 2006 as compared to the same period in 2005. Actual product gross margin percentages for the three months ended March 31, 2006 and March 31, 2005 were 27% and 30% respectively. This decrease reflects the lower average selling prices described above, partially offset by reduced costs of the 1 megabit device.

Research and Development

We believe that continued investments in new product development are required for us to remain competitive in the markets we serve. In 2005, our research and development department continued its efforts on the development, testing and qualification of our 1-megabit 3-volt nvSRAM with DBE. In September 2005, we qualified our 1-megabit products for use in the commercial and industrial markets. Final qualification of the smaller 256-kilobit and 256-kilobit with real time clock, and the 1-megabit version with real time clock, built on the 0.25-micron process at DBE is expected in the second quarter of 2006.

During the first quarter of 2006, we continued the development of our next generation nvSRAM product family, in conjunction with Cypress, pursuant to the terms of the May 5, 2005 development agreement. This new product family will be based on Cypress' 0.13-micron "S8" process and we expect it will include memory densities up to and beyond 4-megabits. In the first quarter of 2006 we achieved our third major milestone under the development agreement, as scheduled. There were no similar expenses in the first quarter of 2005.

As part of our strategic product development activities, on March 24, 2006, Simtek entered into a License and Development Agreement with Cypress which expands the agreement the two companies signed in May 2005. Under the terms of the new agreement:

- o Cypress will retain the right to include nvSRAM functionality on future programmable system-on-chip (PSoC(TM)) and customized integrated circuits originally granted in the May 2005 agreement, and now with clearly defined royalty payments to Simtek for the use of its SONOS-based nvSRAM intellectual property;
- o Simtek is granted the right to use certain intellectual property of Cypress in developing future generation nvSRAM products, including the jointly developed 0.13u SONOS-based CMOS process, advanced SRAM IP, design-related IP, design-for-manufacturability know-how; and other IP related to Cypress' advanced CMOS manufacturing processes and procedures;

Edgar Filing: SIMTEK CORP - Form 10-Q/A

- o Simtek and Cypress agree to broad manufacturing support terms that will provide Simtek with a range of industry-leading manufacturing skills and know-how to enable cost-effective manufacturing of leading-edge SONOS nvSRAMs;
- o Simtek and Cypress will extend the deployment of Simtek's proprietary nvSRAM technology, and work to establish SONOS as the preferred technology for high reliability, high endurance, and scaleable non-volatile products at 65nm and below;
- o Simtek and Cypress will jointly develop and market a family of products utilizing Simtek's patented SONOS-based non-volatile technology for production using Cypress's advanced manufacturing processes.

18

SIMTEK CORPORATION

Upon signing the agreement, Simtek received \$2 million from Cypress, and will receive additional payments of \$1 million on June 30, 2006 and December 31, 2006. The agreement also calls for Simtek to issue warrants to Cypress to purchase a total of 20 million shares of its common stock, 10 million of which were already issued upon the execution of the agreement, 5 million of which are expected to be issued on June 30, 2006 upon the payment by Cypress of certain royalties and 5 million of which are expected to be issued on December 31, 2006 upon the payment by Cypress of certain royalties. The warrants have, or will have, an exercise price of \$0.75 per share. Simtek believes that this new agreement will accelerate the timing of expanding nvSRAM adoption in new markets and shorten future product development cycle time. Please read Note 6 to the Condensed Consolidated Financial Statements for a discussion of the accounting treatment for the transactions related to this agreement.

Total research and development expenses were \$1,545,000 for the three months ended March 31, 2006 as compared to \$1,145,000 for the same period in 2005. The \$400,000 increase for the three month period was primarily related to an increase of \$315,000 related to the co-development with Cypress and \$80,000 related to final development of the 256-kilobit nvSRAM products built at DBE.

Administration

Total administration expenses were \$699,000 for the three months ended March 31, 2006 as compared to \$293,000 for the same period in 2005.

The \$406,000 increase was due primarily to increases in payroll and payroll related costs of \$162,000, accounting and legal fees of \$88,000, travel of \$41,000, contract services of \$38,000, expense related to employee and director stock options of \$64,000 and miscellaneous expenses of \$13,000. The increase in payroll and payroll overhead costs were due to additional headcount and the management restructure that began in May 2005. The increase in professional services was primarily due to increased legal and accounting fees, which were related to increased activity related to agreements with personnel and increased securities work. The increase of \$64,000 in employee and director stock option expense was due to the requirement of expensing costs related to stock option grants under FAS 123. See Note 1 to the Notes to the Condensed Consolidated Financial Statements above.

Edgar Filing: SIMTEK CORP - Form 10-Q/A

Sales and Marketing

Total sales and marketing expenses were \$944,000 for the three months ended March 31, 2006 as compared to \$401,000 for the same period in 2005.

The \$543,000 increase was due primarily to amortization of the non-compete agreement with ZMD of \$448,000, an increase in payroll and payroll overhead costs of \$67,000, expense related to employee stock options of \$16,000 and miscellaneous other expenses. The increase in payroll and payroll overhead costs were due to changes in sales and marketing personnel.

Net Loss from Continuing Operations

We recorded a loss from continuing operations of \$901,000 and \$987,000 for the three months ended March 31, 2006 and 2005, respectively. The decrease of \$86,000 for the three-month period reflects the revenue and expense items discussed above.

Liquidity and Capital Resources

As of March 31, 2006, we had a net working capital of \$5,881,000 as compared to a net working capital of \$3,591,000 as of December 31, 2005.

As discussed previously, on March 24, 2006, we entered into a Development and License Agreement with Cypress pursuant to which, among other things, Cypress has agreed to license certain intellectual property from us to develop and manufacture standard, custom, and embedded nvSRAM products. Cypress will pay to Simtek royalties across all products they develop and sell which include intellectual property licensed from Simtek. We agreed to license from Cypress certain of their intellectual property for use in our design efforts. We agreed with Cypress to co-develop certain nvSRAM products and Cypress has agreed to pay us \$4 million in pre-paid royalties, \$2 million of which was received at the

SIMTEK CORPORATION

time the contract was executed. The remaining \$2 million will be paid in \$1 million payments the first of which is scheduled for June 30, 2006, and the final one scheduled for December 31, 2006. In addition, we agreed with Cypress to work together to develop new products and processes. Please read Note 7 to the Condensed Consolidated Financial Statements for a discussion of the accounting treatment for the transactions related to this agreement.

Cash flows used in operating activities for the three months ended March 31, 2006 were \$1,580,000 compared to \$531,000 in the same period in 2005, an increase of \$1,049,000 as compared to the same period in 2005. The net change is due to the decreased net loss, the increase in accounts receivable (compared to a decrease in the 2005 period), a larger increase in inventory, which were partially offset by the non-cash charges in 2006. The increase in inventory for the three months ended March 31, 2006 was due primarily to higher volume of silicon wafers and units in process, which will support future revenue.

Cash flows used in investing activities decreased for the three months ended March 31, 2006 by approximately \$14,000 as compared to the same period in 2005.

Edgar Filing: SIMTEK CORP - Form 10-Q/A

The increase of \$2,781,000 in cash flows provided by financing activities was primarily due to the receipt of funds related to the sale of common stock completed on December 30, 2005, for which some funds were received on January 3, 2006 and the value of the warrants issued to Cypress for the Development and License Agreement.

Short-term liquidity.

Our cash balance at March 31, 2006 was \$2,814,000.

Our future liquidity will depend on our revenue growth and our ability to sell our products at positive gross margins and control of our operating expenses. Through December 31, 2006, we expect to spend approximately \$9,000,000, for operating expenses assuming revenue growth. We expect to meet these capital needs from sales revenues, the funds still due to us from Cypress under the Joint Development and License Agreement and, to the extent we do not have sufficient revenues, from our existing cash reserves.

Long-term liquidity.

Based on current revenue, cost and profitability projections, current working capital, plus the additional prepaid royalties due from Cypress, the Company believes that it has adequate capital to sustain its operations for the foreseeable future. However, the Company is also negotiating with a bank to provide an accounts receivable based credit facility to provide additional capital if needed.

ITEM 3 QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Market risk represents the risk of loss that may impact our financial

Edgar Filing: SIMTEK CORP - Form 10-Q/A

position, results of operations or cash flows due to adverse changes in financial and commodity market prices and rates. We are exposed to market risk in the areas of changes in United States interest rates and changes in foreign currency exchange rates as measured against the United States dollar. These exposures are directly related to our normal operating activities. We currently have no derivative financial instruments.

Interest payable on our convertible debentures is fixed at 7.5% over the term of the debentures. As such, changes in interest rates will not affect future expenses or cash flows.

We manage interest income by investing our excess cash in cash equivalents bearing variable interest rates, which are tied to various market indices. We do not believe that near-term changes in interest rates will result in a material effect on future earnings, fair values or cash flows.

We do not speculate in the foreign exchange market and do not manage exposures that arise in the normal course of business related to fluctuations in foreign currency exchange rates by entering into offsetting positions through the use of foreign exchange forward contracts.

Average selling prices of our products have not increased significantly as a result of inflation during the past several years, primarily due to intense competition within the semiconductor industry. The effect of inflation on our costs of production has been minimized through improvements in production efficiencies. We anticipate that these factors will continue to minimize the effects of any foreseeable inflation and other price pressures within the industry and markets in which we participate.

ITEM 4 CONTROLS AND PROCEDURES

(a) Evaluation of disclosure controls and procedures.

Harold Blomquist, who serves as the Company's chief executive officer, and Brian Alleman, who serves as the Company's chief financial officer, after evaluating the effectiveness of the Company's disclosure controls and procedures as of the end of the period covered by this quarterly report (the "Evaluation Date") concluded that as of the Evaluation Date, the Company's disclosure controls and procedures were effective to ensure that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported as specified in the SEC's rules and forms and to ensure that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is accumulated and communicated to our management to allow timely decisions regarding required disclosure.

(b) Changes in internal control over financial reporting.

There were no changes in the Company's internal control over financial reporting during the three months ended March 31, 2006, that have materially affected, or are reasonably likely to materially affect, internal control over financial reporting.

SIMTEK CORPORATION

PART II. OTHER INFORMATION

Item 1. Legal Proceedings - None

Item 1A. Risk Factors - None

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds - None

Item 3. Defaults upon Senior Securities - None

Item 4. Submission of Matters to a Vote of Security Holders - None

Item 5. Other Information. The following information was not required to be disclosed on Form 8-K during the quarter ended March 31, 2006, but rather is included in this Quarterly Report on Form 10-Q pursuant to Exchange Act Rule 14a-5(f). The Company expects to hold its annual meeting of shareholders on June 29, 2006, subject to the discretion of our Board of Directors to change such date based on changed circumstances. As a consequence of having advanced the date of the annual meeting of shareholders by more than 30 days from the date of the previous annual meeting, the deadline for the Company's receipt of stockholder proposals for inclusion in the proxy statement is a reasonable time before we begin to print and mail the proxy solicitation materials, as disclosed in the proxy statement for the 2005 annual meeting. Also as disclosed in the proxy statement for the 2005 annual meeting, a shareholder proposal or nomination for director for consideration at the 2006 annual meeting but not included in the proxy statement and proxy must be received by the Company no later than 30 days prior to the first anniversary of the initial notice of the 2005 annual meeting, provided that such proposal need not be given more than 50 days prior to the first anniversary of the initial notice of the 2005 annual meeting.

Item 6. Exhibits

- | | |
|------|---|
| 10.1 | License and Development Agreement, dated March 24, 2006, by and between the Company and Cypress Semiconductor Corporation, incorporated by reference to the Company's Current Report on Form 8-K filed by the Company with the SEC on March 30, 2006 |
| 10.2 | Amended and Restated Registration Rights Agreement, dated March 24, 2006, by and between the Company and Cypress Semiconductor Corporation, incorporated by reference to the Company's Current Report on Form 8-K filed by the Company with the SEC on March 30, 2006 |
| 31.1 | Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 of Principal Executive Officer |

Edgar Filing: SIMTEK CORP - Form 10-Q/A

- 31.2 Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 of Principal Financial Officer
- 32.1 Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 of Principal Executive Officer
- 32.2 Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 of Principal Financial Officer

23

SIMTEK CORPORATION

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

SIMTEK CORPORATION
(Registrant)

August 4, 2006

By: /s/ Harold Blomquist

HAROLD BLOMQUIST
Chief Executive Officer and President

August 4, 2006

By: /s/ Brian Alleman

BRIAN ALLEMAN
Chief Financial Officer

24

valign=top width=60.933>

First Quarter

62.00

68.18

57.25

68.36

58.60

On February 22, 2008, we had 565 holders of record of Class A Common Stock and 182 holders of record of Class B Common Stock. Bio-Rad has never paid a cash dividend and has no present plans to pay cash dividends.

See Item 12 for the security ownership of certain beneficial owners and management and for securities authorized for issuance under equity compensation plans.

The section headed "Stock Performance Graph" in the Annual Report to Stockholders for the fiscal year ended December 31, 2007 is incorporated herein by reference.

ITEM 6. SELECTED FINANCIAL DATA

The table headed "Summary of Operations and Selected Financial Data" appearing on page 1 of Exhibit 13.1 is incorporated herein by reference.

**ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS**

The section headed "Management's Discussion and Analysis of Results of Operations and Financial Condition" appearing on pages 40 through 52 of Exhibit 13.1 is incorporated herein by reference.

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES

ABOUT MARKET RISK

The section headed Financial Risk Management appearing on pages 51 and 52 of Exhibit 13.1 is incorporated herein by reference.

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

The Consolidated Financial Statements and Notes thereto and the Report of Independent Registered Public Accounting Firm appearing on pages 2 through 39 of Exhibit 13.1 are incorporated herein by reference.

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

None.

ITEM 9A. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this report, Bio-Rad carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective to provide reasonable assurance that material information relating to Bio-Rad is made known to management, including the Chief Executive Officer and Chief Financial Officer.

Changes in Internal Control Over Financial Reporting

There has been no change in our internal controls over financial reporting during our most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal controls over financial reporting.

Management's Report on Internal Control Over Financial Reporting

The management of Bio-Rad Laboratories, Inc. is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rule 13a-15(f) under the Securities and Exchange Act of 1934, as amended (the "Exchange Act"). Our internal control system is designed to provide reasonable assurance regarding the preparation and fair presentation of our financial statements presented in accordance with generally accepted accounting principles.

An internal control system over financial reporting has inherent limitations and may not prevent or detect misstatements. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation.

Management has used the framework set forth in the report entitled *Internal Control – Integrated Framework* published by the Committee of Sponsoring Organizations (COSO) of the Treadway Commission to evaluate the effectiveness of Bio-Rad's internal control over financial reporting as of December 31, 2007. Our assessment of and conclusion on the effectiveness of internal control over financial reporting did not include the internal controls of DiaMed Holding AG, Inc., acquired on October 1, 2007, which are included in our fiscal 2007 consolidated financial statements and which consisted of 42% and 31% of net and total assets, respectively, and 4% of revenues of the consolidated financial statement amounts as of and for the year ended December 31, 2007. Based on that evaluation, our management concluded that our internal control over financial reporting was effective as of December 31, 2007 to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external reporting purposes in accordance with accounting principles generally accepted in the United States of America. We reviewed the results of management's assessment with the Audit Committee of our Board of Directors.

Deloitte & Touche LLP, an independent registered public accounting firm, has audited the consolidated financial statements of Bio-Rad Laboratories, Inc. for the three years ended December 31, 2007 and have issued an attestation report on the effectiveness of Bio-Rad's internal control over financial reporting, as stated in their report.

ITEM 9B. OTHER INFORMATION

None.

PART III

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

Part of the information required to be furnished pursuant to this item is incorporated by reference from portions of Bio-Rad's definitive proxy statement to be mailed to stockholders in connection with its 2008 annual meeting of stockholders (the *2008 Proxy Statement*) under Election of Directors, Committees of the Board of Directors and Section 16(a) Beneficial Ownership Reporting Compliance.

Bio-Rad's Board of Directors has determined that Mr. Ruediger Naumann-Etienne and Mr. Louis Drapeau are audit committee financial experts, as defined in Item 401(h) of Regulation S-K. Mr. Naumann-Etienne and Mr. Drapeau are also independent directors, as determined in accordance with the independence standards set forth in Rule 10A-3 under the Securities Exchange Act of 1934, as amended, and Section 121A of the American Stock Exchange Company Guide.

We have adopted a code of business ethics and conduct that applies to our principal executive officer, principal financial officer, principal accounting officer or controller and all other employees. We will provide a copy of the code of ethics to any person, without charge, upon request, by writing to us at Bio-Rad Laboratories, Inc., Investor Relations, 1000 Alfred Nobel Drive, Hercules, CA 94547.

ITEM 11. EXECUTIVE COMPENSATION

The information required to be furnished pursuant to this item is incorporated by reference from portions of the 2008 Proxy Statement under Compensation Discussion and Analysis, Summary Compensation Table, Grants of Plan-Based Awards, Outstanding Equity Awards, Option Exercises and Stock Vested Table, Pension Benefits, Nonqualified Defined Contribution and Other Nonqualified Deferred Compensation Plans, Potential Payments on Termination or Change in Control, Director Compensation and Compensation Committee Interlocks and Insider Participation. In addition, the information from a portion of the 2008 Proxy Statement under Compensation Committee Report is incorporated herein by reference and furnished on this Form 10-K and shall not be deemed filed for purposes of Section 18 of the Securities and Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933.

**ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS
AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS**

Part of the information required to be furnished pursuant to this item is incorporated by reference from a portion of the 2008 Proxy Statement under Principal and Management Stockholders.

Plan category	Number of securities	Weighted-average exercise price of outstanding options, warrants and rights	Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a))
	to be issued upon exercise of outstanding options, warrants and rights (a)		
Equity compensation plans approved by security holders ⁽¹⁾	1,418,401	\$ 43.64	1,916,402 ⁽²⁾
Equity compensation plans not approved by stockholders	—	—	—
Total	<u>1,418,401</u>	<u>\$ 43.64</u>	<u>1,916,402</u>

- (1) Consists of the Bio-Rad Laboratories, Inc. 1994 Stock Option Plan, the 2003 Stock Option Plan of Bio-Rad Laboratories, Inc., the Bio-Rad Laboratories, Inc. 2007 Incentive Award Plan and the Bio-Rad Laboratories, Inc. Amended and Restated 1988 Employee Stock Purchase Plan.
- (2) Consists of 1,490,240 shares available under the Bio-Rad Laboratories, Inc. 2007 Incentive Award Plan and 426,162 shares available for issuance under the Bio-Rad Laboratories, Inc. Amended and Restated 1988 Employee Stock Purchase Plan.

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

The information required to be furnished pursuant to this item is incorporated by reference from portions of the 2008 Proxy Statement under Transactions with Related Persons and Committees of the Board of Directors.

ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES

The information required to be furnished by this item is incorporated by reference from a portion of the 2008 Proxy Statement under Report of the Audit Committee of the Board of Directors.

P A R T I V

ITEM 15.

EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

(a) Index to Financial Statements

1.

The following Consolidated Financial Statements are included in Exhibit 13.1 and are incorporated herein by reference pursuant to Item 8:

Page in
Exhibit 13.1

Consolidated Balance Sheets at December 31, 2007 and 2006 2-3

Consolidated Statements of Income for each of the three years
in the period ended December 31, 2007 4

Consolidated Statements of Cash Flows for each of the
three years in the period ended December 31, 2007 5

Consolidated Statements of Changes in Stockholders'
Equity
for each of the three years in the period ended December
31, 2007 6

Notes to Consolidated Financial Statements 7-37

Report of Independent Registered Public Accounting
Firm 38-39

2. Index to Financial Statement Schedule

Page in
Form 10-K

Schedule II Valuation and Qualifying Accounts 18

All other financial statement schedules are omitted because they are not required or the required information is included in the Consolidated Financial Statements or the Notes thereto.

3. Index to Exhibits

The exhibits listed in the accompanying Index to Exhibits on pages 21 through 25 of this report are filed or incorporated by reference as part of this report.

BIO-RAD LABORATORIES, INC.

SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS

Years Ended December 31, 2007, 2006 and 2005

(In thousands)

Reserve for doubtful accounts receivable

	Balance at Beginning of Year	Additions Charged to Costs and Expenses	Deductions	Other (A)	Balance at End of Year
2007	\$ 15,265	\$ 3,925	\$ (3,227)	\$ 5,447	\$ 21,410
2006	\$ 13,301	\$ 1,931	\$ (537)	\$ 570	\$ 15,265
2005	\$ 13,406	\$ 1,669	\$ (1,774)	--	\$ 13,301

(A) Due to acquisitions.

Valuation allowance for current and long-term deferred tax assets

	Balance at Beginning of Year	Additions	Deductions Charged to Costs and Expenses	Other (B)	Balance at End of Year
2007	\$ 26,494	\$ 9,079	\$ (5,551)	\$ 1,097	\$ 31,119
2006	\$ 17,737	\$ 6,102	\$ (1,770)	\$ 4,425	\$ 26,494
2005	\$ 18,023	\$ 4,590	\$ (4,876)	--	\$ 17,737

(B) Due to acquisitions.

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

Board of Directors and Stockholders

Bio-Rad Laboratories, Inc.

Hercules, California

We have audited the consolidated financial statements of Bio-Rad Laboratories, Inc. and subsidiaries (the "Company") as of December 31, 2007 and 2006, and for each of the three years in the period ended December 31, 2007, and the Company's internal control over financial reporting as of December 31, 2007, and have issued our report thereon dated February 29, 2008 (which report on the financial statements expresses an unqualified opinion and includes an explanatory paragraph concerning the adoption of new accounting standards in 2007 and 2006); such report is included elsewhere in this Form 10-K. Our audits also included the consolidated financial statement schedule of the Company listed in Item 15(a)2. This consolidated financial statement schedule is the responsibility of the Company's management. Our responsibility is to express an opinion based on our audits. In our opinion, such consolidated financial statement schedule, when considered in relation to the basic consolidated financial statements taken as a whole, presents fairly, in all material respects, the information set forth therein.

/s/ Deloitte Touche LLP
San Francisco, California
February 29, 2008

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

BIO-RAD LABORATORIES, INC.

By: /s/ Sanford S. Wadler
Sanford S. Wadler
Secretary

Date: February 29, 2008

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

Principal Executive Officer:

<u>/s/ Norman Schwartz</u> (Norman Schwartz)	President and Director	February 29, 2008
---	------------------------	-------------------

Principal Financial Officer

<u>/s/ Christine A. Tsingos</u> (Christine A. Tsingos)	Vice President, Chief Financial Officer	February 29, 2008
---	--	-------------------

Principal Accounting Officer

<u>/s/ James R. Stark</u> (James R. Stark)	Corporate Controller	February 29, 2008
---	----------------------	-------------------

Other Directors:

<u>/s/ James J. Bennett</u> (James J. Bennett)	Director	February 29, 2008
---	----------	-------------------

Edgar Filing: SIMTEK CORP - Form 10-Q/A

<u>/s/ Louis Drapeau</u> (Louis Drapeau)	Director	February 29, 2008
<u>/s/ Albert J. Hillman</u> (Albert J. Hillman)	Director	February 29, 2008
<u>/s/ Ruediger Naumann-Etienne</u> (Ruediger Naumann-Etienne)	Director	February 29, 2008
<u>/s/ Alice N. Schwartz</u> (Alice N. Schwartz)	Director	February 29, 2008
<u>/s/ David Schwartz</u> (David Schwartz)	Director	February 29, 2008

BIO-RAD LABORATORIES, INC.

INDEX TO EXHIBITS ITEM 15(a)3

Exhibits 32.1 and 32.2 are furnished herewith and should not be deemed to be filed under the Securities Exchange Act of 1934.

Exhibit No.

- | | |
|-------|--|
| 2.1 | Share Purchase Agreement as of May 14, 2007 by and among Bio-Rad Laboratories, Inc. and certain selling shareholders regarding the purchase of 77.6765% of the equity of DiaMed Holding AG. (17) |
| 3.1 | Restated Certificate of Incorporation, as of February 8, 2002. (1) |
| 3.1.1 | Certificate of Amendment to Restated Certificate of Incorporation of Bio-Rad Laboratories, Inc., as of May 6, 2004. (2) |
| 3.2 | Bylaws of the Registrant, as amended February 19, 1980. (3) |
| 4.1 | Credit Agreement dated as of September 9, 2003 among Bio-Rad Laboratories, Inc., the lenders, Bank One, N.A., as Administrative Agent, Wells Fargo Bank, N.A. and Union Bank of California, N.A., as Syndication Agents and ABN AMRO Bank N.V. and BNP Paribas, as Documentation Agents. (4) |
| 4.1.1 | Amendment No. 1 to Credit Agreement dated as of December 8, 2004 among Bio-Rad Laboratories, Inc., the lenders referred to herein, JPMorgan Chase Bank, N.A. (successor by merger to Bank One, NA (Illinois)), as lender and Administrative Agent, Wells Fargo Bank, N.A. and Union Bank of California, N.A., as Syndication Agents and ABN AMRO Bank N.V. and BNP Paribas, as Documentation agents. (5) |
| 4.1.2 | Amendment No. 2 to Amended and Restated Credit Agreement dated as of September 27, 2007 among Bio-Rad Laboratories, Inc., the lenders referred to herein, and JPMorgan Chase Bank, N.A. (successor by merger to Bank One, NA (Main Office |

Chicago), as lender and contractual representative. (18)

- 4.2 Pledge Amendment dated as of September 9, 2003 among Bio-Rad Laboratories, Inc., and Bank One, N.A., as contractual representative. (4)
- 4.3 Security Agreement dated as of September 9, 2003 among Bio-Rad Laboratories, Inc.,
as Grantor and Bank One N.A., as Administrative Agent. (4)
- 4.4 Indenture dated as of August 11, 2003 for 7.50% Senior Subordinated Notes due 2013
among Bio-Rad Laboratories, Inc., as Issuer, and Wells Fargo Bank, N.A.,
as
Trustee. (4)

- 4.5 The Exchange and Registration Rights Agreement dated as of August 11, 2003 for 7.50% Senior Subordinated Notes due 2013. (4)
- 4.6 Indenture dated as of December 21, 2004, between Bio-Rad Laboratories, Inc. and Wells Fargo National Bank, as trustee. (6)
- 10.1 Amended and Restated Credit Agreement, dated as of June 21, 2005, by and among Bio-Rad Laboratories, Inc., the lenders referred to therein, JPMorgan Chase Bank, N.A. (successor by merger to Bank One, NA(Main Office Chicago)), as a lender and administrative agent, Wells Fargo Bank, N.A. and Union Bank of California N.A., as syndication agents and ABN AMRO Bank N.V. and BNP Paribas, as documentation agents. (7)
 - 10.1.1 Amendment No. 1 to Amended and Restated Credit Agreement. (8)
- 10.2 Amended and Restated Security Agreement, dated as of June 21, 2005, between Bio-Rad Laboratories, Inc. and JPMorgan Chase Bank, N.A. (successor by merger to Bank One, NA (Main Office Chicago)), as administrative agent. (7)
- 10.3 Amended and Restated Pledge Agreement, dated as of June 21, 2005, between Bio-Rad Laboratories, Inc. and JPMorgan Chase Bank, N.A. (successor by merger to Bank One, NA (Main Office Chicago)), as administrative agent. (7)
- 10.4 1994 Stock Option Plan. (9)
 - 10.4.1 Amendment to the Bio-Rad Laboratories, Inc. 1994 Stock Option Plan dated April 28, 1998. (10)
 - 10.4.2 Second Amendment to the Bio-Rad Laboratories, Inc. 1994 Stock Option Plan dated December 6, 1999. (10)
 - 10.4.3 Third Amendment to the Bio-Rad Laboratories, Inc. 1994 Stock Option Plan dated September 19, 2000. (10)
 - 10.4.4 Fourth Amendment to the Bio-Rad Laboratories, Inc. 1994 Stock Option Plan dated April 25, 2001. (11)
- 10.5 Amended and Restated 1988 Employee Stock Purchase Plan. (12)

- 10.5.1 Amendment to the Amended 1988 Employee Stock Purchase Plan. (11)
- 10.6 Employees' Deferred Profit Sharing Retirement Plan (Amended and Restated effective January 1, 1997). (13)
- 10.7 2003 Stock Option Plan. (14)

- 10.7.1 Amendment to the 2003 Stock Option Plan of Bio-Rad Laboratories, Inc. (19)
- 10.8 2007 Incentive Award Plan (21)
- 10.10 Non-competition and employment continuation agreement with James J. Bennett. (15)
- 10.13 Stock Purchase Agreement dated as of August 16, 2004 by and between Bio-Rad, MJ GeneWorks, Incorporated, Michael J. Finney and John D. Finney, excluding exhibits and schedules. Pursuant to Regulation S-K Item 601(b)(2), the exhibits and schedules to this agreement have not been filed. We agree to furnish supplementally a copy of any omitted exhibits or schedules to the SEC upon request. We have requested confidential treatment of certain portions of this agreement. (16)
- 10.14 Connecticut Settlement Agreement dated as of February 9, 2006 by and between Bio-Rad Laboratories, Inc., MJ Research, Inc., and Applera Corporation, through its Applied Biosystems Group. (16)
- 10.15 Real-Time Settlement Agreement dated as of February 9, 2006 by and between Bio-Rad Laboratories, Inc., MJ Research Inc., and Applera Corporation, through its Applied Biosystems Group. (16)
- 10.15.1 Amendment No. 1 to Real-Time Settlement Agreement dated as of May 4, 2007 by and between Bio-Rad Laboratories, Inc., MJ Research, Inc. and Applera Corporation, through its Applied Biosystems Group.(20)
- 10.16 Amended and Restated Thermal Cycler Supplier Agreement dated as of February 9, 2006 by and between Bio-Rad Laboratories, Inc., MJ Research, Inc. and Applera Corporation, through its Applied Biosystems Group. (16)
- 10.17 Real-Time Instrument Patent License Agreement dated as of February 9, 2006, by and between Bio-Rad Laboratories, Inc., Mj Research, Inc., and Applera Corporation through its Applied Biosystems Group. (16)
- 10.17.1 Amendment No. 1 to Real-Time Patent License Agreement dated as of May 4, 2007 by and between Bio-Rad Laboratories, Inc., MJ Research, Inc. and Applera Corporation through its Applied Biosystems Group.(20)

Edgar Filing: SIMTEK CORP - Form 10-Q/A

- 13.1 Excerpt from Annual Report to Stockholders' for the fiscal year ended December 31, 2007 (to be deemed filed only to the extent required by the instructions to exhibits for reports on Form 10-K).
- 21.1 Listing of Subsidiaries.
- 23.1 Consent of Independent Registered Public Accounting Firm.
- 31.1 Certification of Chief Executive Officer Required by Rule 13a-14(a) (17CFR 240.13a-14(a)).

- 31.2 Certification of Chief Financial Officer Required by Rule 13a-14(a) (17CFR 240.13a-14(a)).
- 32.1 Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
- 32.2 Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
- (1) Incorporated by reference from the Exhibits to Bio-Rad's Form 10-K filing for the fiscal year ended December 31, 2001, dated March 28, 2002.
- (2) Incorporated by reference from the Exhibits to Bio-Rad's Form 10-K filing for the fiscal year ended December 31, 2004, dated March 3, 2005.
- (3) Incorporated by reference from the Exhibits to Bio-Rad's Registration Statement on Form S-7 Registration No. 2-66797, which became effective April 22, 1980.
- (4) Incorporated by reference from the Exhibits to Bio-Rad's Form S-4 dated September 19, 2003.
- (5) Incorporated by reference from the Exhibits to Bio-Rad's Form 8-K filing dated December 14, 2004.
- (6) Incorporated by reference from the Exhibits to Bio-Rad's Form 8-K filing, dated December 22, 2004.
- (7) Incorporated by reference from the Exhibits to Bio-Rad's Form 8-K filing, dated June 24, 2005.
- (8) Incorporated by reference from the Exhibits to Bio-Rad's September 30, 2005 10-Q filing, dated November 8, 2005
- (9) Incorporated by reference from the Exhibits to Bio-Rad's Form S-8 filing, dated

April 29, 1994.

- (10) Incorporated by reference from the Exhibits to Bio-Rad's Form 10-K filing for the fiscal year ended December 31, 2000, dated March 28, 2001.
- (11) Incorporated by reference from the Exhibits to Bio-Rad's Form 10-K filing for the fiscal year ended December 31, 2003, dated March 15, 2004.
- (12) Incorporated by reference from the Exhibits to Bio-Rad's September 30, 1998, Form 10-Q filing, dated November 12, 1998.

- (13) Incorporated by reference from the Exhibits to Bio-Rad s September 30, 1997, Form 10-Q filing, dated November 13, 1997.
- (14) Incorporated by reference from the Exhibits to Bio-Rad s March 31, 2003, Form 10-Q filing, dated May 13, 2003.
- (15) Incorporated by reference from the Exhibits to Bio-Rad s December 31, 1996 Form 10-K filing, dated March 27,1997.
- (16) Incorporated by reference from the Exhibits to Bio-Rad s March 31, 2006 Form 10-Q filing, dated May 9, 2006.
- (17) Incorporated by reference from the Exhibits to Bio-Rad s May 14, 2007 Form 8-K filing, dated May 14, 2007.
- (18) Incorporated by reference from the Exhibits to Bio-Rad s September 27, 2007 Form 8-K filing, dated October 3, 2007.
- (19) Incorporated by reference from the Exhibits to Bio-Rad s March 31, 2007 Form 10-Q filing, dated May 4, 2007.
- (20) Incorporated by reference from the Exhibits to Bio-Rad s June 30, 2007 Form 10-Q filing, dated August 8, 2007.
- (21) Incorporated by reference from the Exhibits to Bio-Rad s S-8 filing, dated July 30, 2007.